BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that a poster presentation including Phase 2 clinical data on its lead drug candidate, BIND-014, in patients with non-small cell lung cancer (NSCLC) will be presented at the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The meeting, which is hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), takes place November 18-21, 2014, in Barcelona, Spain.
BIND-014 is a PSMA targeted polymeric nanoparticle containing the cytotoxic agent docetaxel. In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel in tumors which translated to marked improvements in antitumor activity. In a Phase 1 study, BIND-014 was well tolerated and showed initial indications of anti-tumor activity. BIND-014 is currently in two Phase 2 trials for the treatment of non-small cell lung cancer and metastatic castrate resistant prostate cancer.
Details of the poster presentation at EORTC-NCI-AACR:
- (Abstract #41 ): Wednesday, November 19, 2014, through Friday November 20, 2014, from 9:00 a.m. to 4:00 p.m. GMT, Title: “Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer,” J. Summa, BIND Therapeutics, Poster Board #035, Session: Cytotoxics, Location: Exhibition Hall.